

Mary Lou Affronti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9098381/publications.pdf>

Version: 2024-02-01

29
papers

812
citations

623734
14
h-index

552781
26
g-index

29
all docs

29
docs citations

29
times ranked

850
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	2.2	9
2	Response to the letter to the Editor concerning manuscript entitled, “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide” <i>Supportive Care in Cancer</i> , 2020, 28, 5591-5592.	2.2	1
3	Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 684-692.	0.4	1
4	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 43-48.	1.7	5
5	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. <i>Oncologist</i> , 2018, 23, 889-e98.	3.7	26
6	Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. <i>Supportive Care in Cancer</i> , 2018, 26, 557-564.	2.2	49
7	Introduction. <i>Seminars in Oncology Nursing</i> , 2018, 34, 417-419.	1.5	0
8	Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 472-485.	1.5	7
9	Development of a Professional Practice Model for Neuro-oncology Advanced Practitioners at an Academic Medical Center: A Quality Improvement Project. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 475-486.	0.4	0
10	A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 33-40.	2.0	6
11	A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population. <i>Journal of Neuro-Oncology</i> , 2017, 134, 363-369.	2.9	18
12	Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). <i>Supportive Care in Cancer</i> , 2016, 24, 4365-4375.	2.2	9
13	Results of a survey of oncology nurses assessing practice patterns and adherence to antiemetic guidelines.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21647-e21647.	1.6	1
14	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9553-9553.	1.6	1
15	Secondary cancers in long-term survivors of primary glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20616-e20616.	1.6	0
16	Palonosetron in the management of chemotherapy- induced nausea and vomiting in patients receiving multiple-day chemotherapy. <i>Cancer Management and Research</i> , 2014, 6, 329.	1.9	9
17	Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. <i>Supportive Care in Cancer</i> , 2014, 22, 1897-1905.	2.2	28
18	Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9519-9519.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2012, 30, 2074-2074.	1.6	2
20	Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer, 2009, 115, 3501-3511.	4.1	123
21	Consolidation with High-Dose Combination Alkylating Agents with Bone Marrow Transplantation Significantly Improves Disease-Free Survival in Hormone-Insensitive Metastatic Breast Cancer in Complete Remission Compared with Intensive Standard-Dose Chemotherapy Alone. Biology of Blood and Marrow Transplantation, 2006, 12, 195-203.	2.0	30
22	Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology, 2004, 6, 145-153.	1.2	24
23	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology, 2004, 6, 134-144.	1.2	42
24	Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma. Journal of Clinical Oncology, 2003, 21, 646-651.	1.6	246
25	A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 1996, 37, 561-568.	2.3	25
26	Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine, 1995, 7, 471-477.	3.2	60
27	Bone Metastases from Breast Cancer. Journal of Computer Assisted Tomography, 1992, 16, 608-614.	0.9	15
28	High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemotherapy and Pharmacology, 1990, 26, 155-156.	2.3	19
29	The duke afm program intensive induction chemotherapy for metastatic breast cancer. Cancer, 1990, 66, 431-436.	4.1	55